



Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

October 11, 2022 at 3:00 AM EDT

- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing

DURHAM, N.C.--(BUSINESS WIRE)--Oct. 11, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.

Oral Presentation:

Title: Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate Hepatitis B virus *in vivo*

Date and Time: Wednesday, October 12, 2022, 8:30 AM - 10:40 AM BST

Session Title: Parallel 2a, Vaccine technologies & infectious diseases

Location & Poster Number: Pentland and Sidlaw, OR14

Presenter: Derek Jantz, Ph.D., Chief Scientific Officer & Strategy

Poster Presentations:

Title: ARCUS gene editing of Apolipoprotein C3 results in substantial reduction in serum triglycerides *in vivo*

Date and Time: Wednesday, October 12, 2022, 7:30 PM - 9:00 PM BST

Session Title: Gene and epigenetic editing

Location & Poster Number: Cromdale Hall, Level 2, Poster# P441

Presenter: Wendy Shoop, Scientist

Title: Specific elimination of m.3243A>G mutant mitochondrial DNA using mitoARCUS in cultured cells and a novel xenograft mouse model

Date and Time: Thursday, October 13, 2022, 5:30 PM - 7:15 PM BST

Session Title: Gene and epigenetic editing

Location & Poster Number: Cromdale Hall, Level 2, Poster #P422

Presenter: Wendy Shoop, Scientist

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple *ex vivo* "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221011005408/en/): <https://www.businesswire.com/news/home/20221011005408/en/>

Investor Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.